PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

Overview of attention for article published in Frontiers in immunology, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 36,032 followers.

Interesting #radonc https://t.co/Cpi7oDFdeA

20 Aug 2022

Reply Repost Favourite

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study by Yuehong Kong https://t.co/Xt1SQ7cf56

25 Jul 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Op…

16 Jul 2022

Reply Repost Favourite

New Research: PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study: Patients with metastatic cancer refractory to standard systemic therapies have a poor prognosis… https://t.co/

09 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.